Amgen Snatches First FDA Approval For Soliris Biosimilar
Amgen’s Interchangeable Bkemv Is Expected To Launch In The US In March 2025
Amgen has established its frontrunner position in the eculizumab race with a recent FDA approval and an interchangeability designation. Meanwhile, a US District Court has sided with runner-up Samsung Bioepis.
